Laurus Labs is currently trading at Rs. 451.70, up by 13.00 points or 2.96% from its previous closing of Rs. 438.70 on the BSE.
The scrip opened at Rs. 455.10 and has touched a high and low of Rs. 464.35 and Rs. 449.00 respectively. So far 7657 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 579.25 on 22-Dec-2017 and a 52 week low of Rs. 425.00 on 13-Aug-2018.
Last one week high and low of the scrip stood at Rs. 464.35 and Rs. 435.05 respectively. The current market cap of the company is Rs. 4651.53 crore.
The promoters holding in the company stood at 32.06%, while Institutions and Non-Institutions held 49.59% and 18.35% respectively.
Laurus Labs has received an approval from United States Food and Drug Administration (USFDA) for Metformin Hydrochloride Tablets USP 500mg, 850mg and 1,000mg which are used for treatment of diabetes.
Metformin Hydrochloride Tablets USP 500mg, 850mg, and 1000mg are therapeutically equivalent to Glucophage Tablets 500mg, 850mg, and 1000 mg of Bristol-Myers Squibb Company. The Product and API will be commercialized from Company's Unit 2 located at APSEZ, Atchutapuram, Visakhapatnam, in the state of Andhra Pradesh.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1861.70 |
Dr. Reddys Lab | 1391.35 |
Cipla | 1506.35 |
Lupin | 2227.60 |
Zydus Lifesciences | 972.45 |
View more.. |